ArticleNature communications2026
Biomimetic supported catalyst inspired by stalked crinoid.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Supported catalysis is considered as an ideal catalytic mode as it combines the advantages of homogeneous catalysis (activity and selectivity) and heterogeneous catalysis (separation and recyclability). However, its application is greatly limited by the loss of catalytic performance after immobilization of molecular catalyst on supports. Inspired by the upright feeding posture of stalked crinoids-characterized by outstretched arms with ordered pinnules extending away from the substrate-we addressed this issue by immobilizing of a linear polymer catalyst decorated with aluminum porphyrin on silica. Our catalyst demonstrates remarkable productivity (62.4 kg polyols/g Al porphyrin), polymer selectivity (99%) and proton tolerance (320,000 equiv. to [Al]) under highly dilute conditions (0.000125 mol [Al]%, 17.8 ppm) for telomerization of CO
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.